Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs
Authors:
- Philip R. FoxPFPhilip R. Fox
- Mark D. PapichMPMark D. Papich
- Venkata-Rangaro KanikantiVKVenkata-Rangaro Kanikanti
- Ralph KrebberRKRalph Krebber
- Bruce W. KeeneBKBruce W. Keene
- 1 December 2008
- journal article
- clinical trial
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 69 (12) , 1659-1663
Abstract
Objective—To compare the pharmacokinetic properties and bioavailability following oral and IV administration of bisoprolol, a second-generation β1-adrenoceptor–selective blocking agent, with those of carvedilol, a third-generation β1/β2 and α1-adrenoceptor blocking agent, in dogs. Animals—12 healthy adult Beagles. Procedures—A prospective, parallel group study was performed. The dogs were allocated to 1 of 2 groups (6 dogs/group) and were administered orally a 1 mg/kg dose of either bisoprolol or carvedilol. Following a 1-week washout period, each cohort received a 1 mg/kg dose of the same drug IV. Blood samples were collected before and after drug administration, and serum concentrations, pharmacokinetic variables, and bioavailability for each agent were assessed. Results—After oral administration of bisoprolol, the geometric mean value of the area under the concentration-time curve extrapolated to infinity (AUCinf) was 2,195 μg/L (coefficient of variation [CV], 15%). After IV administration of bisoprolol, the dose-normalized geometric mean AUCinf was 2,402 μg/L (CV, 19%). Oral bioavailability of bisoprolol was 91.4%. After oral administration of carvedilol, the geometric mean AUCinf was 70 μg/L (CV, 81%). After IV administration of carvedilol, the geometric mean AUCinf was 491 μg/L (CV, 23%). Oral bioavailability of carvedilol was 14.3%. Total body clearance was low (0.42 L/h/kg) for bisoprolol and high (2.0 L/h/kg) for carvedilol. Conclusions and Clinical Relevance—After oral administration, carvedilol underwent extensive first-pass metabolism and had limited bioavailability; bisoprolol had less first-pass effect and higher bioavailability. Collectively, these differences suggested that, in dogs, bisoprolol has less interindividual pharmacokinetic variability, compared with carvedilol.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogsAmerican Journal of Veterinary Research, 2005
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)Circulation, 2001
- The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialCurrent Controlled Trials in Cardiovascular Medicine, 2001
- β-Adrenergic Receptor Blockade in Chronic Heart FailureCirculation, 2000
- Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogsAmerican Journal of Veterinary Research, 2000
- Prospective, Randomized Comparison of Effect of Long-Term Treatment With Metoprolol or Carvedilol on Symptoms, Exercise, Ejection Fraction, and Oxidative Stress in Heart FailureCirculation, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Second- and Third-Generation Beta-Blocking Drugs in Chronic Heart FailureCardiovascular Drugs and Therapy, 1997
- Comparative Hemodynamic, Left Ventricular Functional, and Antiadrenergic Effects of Chronic Treatment With Metoprolol Versus Carvedilol in the Failing HeartCirculation, 1996